Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy
Autore:
Yoshida, S; Kuriyama, K; Miyazaki, Y; Taguchi, J; Fukushima, T; Honda, M; Hayashibara, T; Nagai, K; Atogami, S; Toriya, K; Soda, H; Nonaka, H; Momita, S; Jinnai, I; Amenomori, T; Kusano, M; Yoshida, Y; Ikeda, S; Matsuo, T; Tomonaga, M;
Indirizzi:
Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 8528523, Japan Nagasaki Univ Nagasaki Japan 8528523 pt Hematol, Nagasaki 8528523, Japan Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Mol Med Unit, Nagasaki 8528523, Japan Nagasaki Univ Nagasaki Japan 8528523 l Med Unit, Nagasaki 8528523, Japan Nagasaki Prefectural Shimabara Onsen Hosp, Shimabara, Japan Nagasaki Prefectural Shimabara Onsen Hosp Shimabara Japan mabara, Japan Nagasaki Municipal Med Ctr, Nagasaki, Japan Nagasaki Municipal Med Ctr Nagasaki Japan ipal Med Ctr, Nagasaki, Japan Nagasaki Municipal Hosp, Nagasaki, Japan Nagasaki Municipal Hosp Nagasaki Japan Municipal Hosp, Nagasaki, Japan Isahaya Insurance Gen Hosp, Isahaya, Japan Isahaya Insurance Gen Hosp Isahaya Japan rance Gen Hosp, Isahaya, Japan Nagasaki Rosai Hosp, Sasebo, Japan Nagasaki Rosai Hosp Sasebo JapanNagasaki Rosai Hosp, Sasebo, Japan Nagasaki Chuo Natl Hosp, Omura, Japan Nagasaki Chuo Natl Hosp Omura Japan gasaki Chuo Natl Hosp, Omura, Japan Japanese Red Cross Nagasaki Atom Bomb Hosp, Nagasaki, Japan Japanese Red Cross Nagasaki Atom Bomb Hosp Nagasaki Japan gasaki, Japan Sasebo Senjyu Hosp, Sasebo, Japan Sasebo Senjyu Hosp Sasebo JapanSasebo Senjyu Hosp, Sasebo, Japan St Francis Hosp, Nagasaki, Japan St Francis Hosp Nagasaki JapanSt Francis Hosp, Nagasaki, Japan Sasebo City Gen Hosp, Sasebo, Japan Sasebo City Gen Hosp Sasebo JapanSasebo City Gen Hosp, Sasebo, Japan Nagasaki Univ Hosp, Blood Transfus Serv, Nagasaki, Japan Nagasaki Univ Hosp Nagasaki Japan Blood Transfus Serv, Nagasaki, Japan
Titolo Testata:
LEUKEMIA RESEARCH
fascicolo: 1, volume: 25, anno: 2001,
pagine: 33 - 38
SICI:
0145-2126(200101)25:1<33:DNAMLI>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE NONLYMPHOCYTIC LEUKEMIA; TRILINEAGE MYELODYSPLASIA; INTENSIVE CHEMOTHERAPY; ONCOLOGY-GROUP; CYTOGENETICS; REMISSION; CRITERIA; FEATURES; THERAPY; CLASSIFICATION;
Keywords:
de novo AML; elderly patient; clinical features; prognostic factors; standard chemotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Kuriyama, K Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol, Sakamoto 1-12-4,Nagasaki 8528523, Japan Nagasaki Univ Sakamoto 1-12-4 NagasakiJapan 8528523 3, Japan
Citazione:
S. Yoshida et al., "De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy", LEUK RES, 25(1), 2001, pp. 33-38

Abstract

To clarify the characteristics of de novo acute myeloid leukemia (AML) among the elderly, we reviewed 112 patients over 60 years old (median age 72 years) who were treated at hospitals in Nagasaki Prefecture with a population of 1.5 million between 1987 and 1994. Reclassification of morphological diagnosis revealed that the proportion of M3 was lower but that of M6 and the incidence of cases with trilineage dysplasia (TLD), known as poor prognostic features, were higher in the elderly than in patients less than 60 years old. Similarly, chromosomal data showed a lower frequency of favorable karyotypes such as t(8;21) and t(15;17) in the elderly. The overall survival of all 112 patients was 10.3% at 5 years. Multivariate analysis indicated that good performance status (PS), low WBC at diagnosis, standard dose multi-drug chemotherapy and all-trans retinoic acid (ATRA) treatment for M3 patients, and morphological findings without TLD were significantly correlated with longer survival. Most of the long-term survivors were found among those who received standard dose therapy in this series, although no consensus has been established how to treat elderly AML patients. We propose that a prospective controlled trial is necessary to confirm the role of standard dose chemotherapy for elderly patients with de novo AML. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 04:09:57